無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大腸炎:パイプライン分析

Colitis - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 232843
出版日 ページ情報 英文 117 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.75円で換算しております。
Back to Top
大腸炎:パイプライン分析 Colitis - Pipeline Review, H1 2019
出版日: 2019年02月01日 ページ情報: 英文 117 Pages
概要

大腸炎とは大腸の炎症であり、ウイルス、寄生虫、食中毒(バクテリア)などによる感染、炎症性疾患(潰瘍性大腸炎・クローン病 )、血流の不足(虚血性大腸炎)、大腸への過去の被爆などさまざまな原因があります。腹痛、鼓腸、血便、悪寒、脱水、下痢、発熱などの症状があり、非ステロイド性抗炎症薬(NSAID)、コルチコステロイドなどの治療法があります。

当レポートでは、世界における大腸炎治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 調査範囲

大腸炎の概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Aerpio Therapeutics, Inc.
  • 味の素製薬
  • Akebia Therapeutics, Inc.
  • Amorepacific Corporation
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dr. Falk Pharma GmbH
  • Galapagos NV
  • Immuron Limited
  • Innate Pharma S.A.
  • Peptinov SAS
  • Pfizer Inc.
  • Prokarium Limited
  • Protalix BioTherapeutics, Inc.
  • RDD Pharma Ltd.
  • Saniona AB
  • Synovo GmbH

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AcTMP-1
  • AKB-4924
  • AKB-6899
  • AN-346
  • 腫瘍治療用ヘパラナーザ阻害抗体
  • 大腸炎治療用抗体
  • 炎症性疾患・大腸炎治療用TNFアルファ阻害アンチセンスRNAiオリゴヌクレオチド
  • APY-0201
  • BC-1215
  • BMS-986104
  • budesonide
  • クロストリジウム・ディフィシレ・ワクチン
  • CSY-0073
  • 炎症性疾患・大腸炎治療用TRP チャネル拮抗薬
  • etanercept biosimilar
  • filgotinib
  • IMM-124E
  • IPH-33
  • mesalamine
  • NK-007
  • PAC-14028
  • Peptide to Inhibit NFkB 大腸炎・腸炎治療用
  • PF-06425090
  • PPV-06
  • RDD-2007
  • クローン病・大腸炎治療用 TNF-アルファ阻害組み換えタンパク質
  • 大腸炎治療薬
  • 大腸炎治療用 Panx1阻害合成ペプチド
  • 大腸炎治療用インターロイキン12/23標的ワクチン
  • 大腸炎治療用インターロイキン23標的ワクチン
  • ZK-216348

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Colitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Colitis - Pipeline by AlfaSigma SpA, H1 2019
  • Colitis - Pipeline by Apollo Endosurgery Inc, H1 2019
  • Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2019
  • Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2019
  • Colitis - Pipeline by enGene Inc, H1 2019
  • Colitis - Pipeline by Genfit SA, H1 2019
  • Colitis - Pipeline by Handa Pharmaceuticals LLC, H1 2019
  • Colitis - Pipeline by Immodulon Therapeutics Ltd, H1 2019
  • Colitis - Pipeline by Immuron Ltd, H1 2019
  • Colitis - Pipeline by Inflazome Ltd, H1 2019
  • Colitis - Pipeline by Nippon Kayaku Co Ltd, H1 2019
  • Colitis - Pipeline by Ogeda SA, H1 2019
  • Colitis - Pipeline by Principia Biopharma Inc, H1 2019
  • Colitis - Pipeline by Protagonist Therapeutics Inc, H1 2019
  • Colitis - Pipeline by RDD Pharma Ltd, H1 2019
  • Colitis - Pipeline by Saniona AB, H1 2019
  • Colitis - Pipeline by Scholar Rock Inc, H1 2019
  • Colitis - Pipeline by Soligenix Inc, H1 2019
  • Colitis - Pipeline by Synthetic Biologics Inc, H1 2019
  • Colitis - Pipeline by Vitality Biopharma Inc, H1 2019
  • Colitis - Dormant Projects, H1 2019
  • Colitis - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Colitis - Dormant Projects, H1 2019 (Contd..2), H1 2019
  • Colitis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Colitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
目次
Product Code: GMDHC11061IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2019, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 24, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Colitis - Overview
  • Colitis - Therapeutics Development
  • Colitis - Therapeutics Assessment
  • Colitis - Companies Involved in Therapeutics Development
  • Colitis - Drug Profiles
  • Colitis - Dormant Projects
  • Colitis - Discontinued Products
  • Colitis - Product Development Milestones
  • Appendix
Back to Top